Compare Incyte Corporation (INCY) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Spotify Technology — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Spotify Technology trades at $489.24 (market cap $103.00B). The key difference: Spotify Technology is far larger — about 4.2× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Spotify Technology nearer its low. Which is the better fit depends on your goals.
| INCY | SPOT | |
|---|---|---|
Market Cap | $24.54B | $103.00B |
Sector | Health | Media |
52-Week High | $129.93 | $738.53 |
52-Week Low | $81.61 | $412.75 |
Enterprise Value | $20.04B | $92.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Spotify (SPOT) trades at $486.44, down 4.96% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong revenue growth to $17.19B in 2025 and net income of $2.21B, with a record 300 million Premium subscribers in Q2 2026. Recent news highlights Spotify's initiative to label AI-generated artists for transparency, reflecting proactive content management.
The outlook remains positive with a consensus price target of $598.20, implying significant upside. Key risks include rising marketing and AI costs impacting margins, as seen in the Q2 2026 earnings miss. Investor sentiment is buoyed by subscriber growth and monetization efforts, but execution on cost control will be critical for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
